Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:DAWNNASDAQ:ESPRNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.31-0.5%$19.19$15.47▼$36.37$697.12M1.47182,486 shs127,339 shsDAWNDay One Biopharmaceuticals$6.28+0.2%$7.19$6.08▼$16.76$638.58M-1.241.11 million shs460,253 shsESPREsperion Therapeutics$0.82+3.4%$1.07$0.69▼$3.94$161.93M0.755.47 million shs3.34 million shsTRVITrevi Therapeutics$6.24-0.8%$6.26$2.30▼$7.39$623.43M0.621.72 million shs628,576 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%+5.43%-2.02%-19.14%+6.03%DAWNDay One Biopharmaceuticals0.00%-3.24%-18.99%-46.95%-54.47%ESPREsperion Therapeutics0.00%-8.52%-14.10%-54.32%-62.90%TRVITrevi Therapeutics0.00%-3.08%-2.78%+39.16%+151.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.1035 of 5 stars3.60.00.00.02.80.00.0DAWNDay One Biopharmaceuticals2.526 of 5 stars4.61.00.00.01.92.50.0ESPREsperion Therapeutics3.5938 of 5 stars3.32.00.03.92.11.70.6TRVITrevi Therapeutics3.5855 of 5 stars4.72.00.00.04.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.14Buy$39.2993.48% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57386.57% UpsideESPREsperion Therapeutics 2.50Moderate Buy$6.25664.99% UpsideTRVITrevi Therapeutics 3.30Buy$17.56181.45% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, AVBP, DAWN, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.005/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.005/7/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.004/25/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/25/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/17/2025ESPREsperion TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.004/8/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ADAWNDay One Biopharmaceuticals$161.92M3.93N/AN/A$3.98 per share1.58ESPREsperion Therapeutics$259.57M0.62N/AN/A($3.85) per share-0.21TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%8/13/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)ESPREsperion Therapeutics-$209.25M-$0.80N/AN/AN/A-29.37%N/A-10.77%8/11/2025 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.45N/AN/AN/AN/A-63.31%-57.06%8/14/2025 (Estimated)Latest ESPR, AVBP, DAWN, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025ESPREsperion Therapeutics-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28DAWNDay One BiopharmaceuticalsN/A14.6214.55ESPREsperion TherapeuticsN/A1.851.37TRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%DAWNDay One Biopharmaceuticals87.95%ESPREsperion Therapeutics47.39%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ADAWNDay One Biopharmaceuticals6.20%ESPREsperion Therapeutics1.00%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.21 millionN/AN/ADAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableESPREsperion Therapeutics200198.20 million195.07 millionOptionableTRVITrevi Therapeutics2099.89 million58.13 millionOptionableESPR, AVBP, DAWN, and TRVI HeadlinesRecent News About These CompaniesNorthern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 27 at 3:03 AM | marketbeat.comWoodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 24 at 5:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 23, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) Buy Rating Reiterated at Needham & Company LLCMay 23, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)May 22, 2025 | marketbeat.comVR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 22, 2025 | marketbeat.comTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughMay 20, 2025 | prnewswire.comPoint72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comWall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?May 14, 2025 | zacks.comTrevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comBarclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 10, 2025 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finanznachrichten.deTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsMay 9, 2025 | marketbeat.comMarshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 8, 2025 | marketbeat.comAlly Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, AVBP, DAWN, and TRVI Company DescriptionsArriVent BioPharma NASDAQ:AVBP$20.30 -0.10 (-0.47%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Day One Biopharmaceuticals NASDAQ:DAWN$6.28 +0.01 (+0.21%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Esperion Therapeutics NASDAQ:ESPR$0.82 +0.03 (+3.38%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Trevi Therapeutics NASDAQ:TRVI$6.24 -0.05 (-0.79%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
